TPST Key Statistics, Chart & Performance
The current stock price of TPST is 2.95 USD. In the past month the price decreased by -9.79%. In the past year, price decreased by -76.16%.
TPST Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About TPST
Company Profile
Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company is headquartered in Brisbane California, California and currently employs 24 full-time employees. The company went IPO on 2012-10-04. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
Company Info
TEMPEST THERAPEUTICS INC
2000 Sierra Point Parkway, Suite 400
Brisbane California CALIFORNIA US
CEO: Louis Arcudi
Employees: 24
Phone: 14157988589
TEMPEST THERAPEUTICS INC / TPST FAQ
What does TPST do?
Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company is headquartered in Brisbane California, California and currently employs 24 full-time employees. The company went IPO on 2012-10-04. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
What is the stock price of TEMPEST THERAPEUTICS INC today?
The current stock price of TPST is 2.95 USD. The price increased by 2.79% in the last trading session.
What is the dividend status of TEMPEST THERAPEUTICS INC?
TPST does not pay a dividend.
What is the ChartMill technical and fundamental rating of TPST stock?
TPST has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the market capitalization of TPST stock?
TEMPEST THERAPEUTICS INC (TPST) has a market capitalization of 14.54M USD. This makes TPST a Nano Cap stock.
What is the next earnings date for TPST stock?
TEMPEST THERAPEUTICS INC (TPST) will report earnings on 2026-03-25, after the market close.
TPST Technical Analysis
TPST Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TPST. The financial health of TPST is average, but there are quite some concerns on its profitability.
TPST Financial Highlights
Over the last trailing twelve months TPST reported a non-GAAP Earnings per Share(EPS) of -10.05. The EPS increased by 50.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -210.49% | ||
| ROE | -568.14% | ||
| Debt/Equity | 0 |
TPST Forecast & Estimates
6 analysts have analysed TPST and the average price target is 9.18 USD. This implies a price increase of 211.19% is expected in the next year compared to the current price of 2.95.